1-20 of 20
Candis Morrison
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Mark Roschewski, Christopher Melani, Rahul Lakhotia, Tatyana Gavrilova, Jagan R. Muppidi, James D. Phelan, Michail S. Lionakis, Kieron Dunleavy, Lode J. Swinnen, Matthias Holdhoff, Catherine E. Lai, Sami Ibrahimi, Michael Glantz, Jan Drappatz, John A. Butman, Stefania Pittaluga, Kim Johnson, Candis Morrison, Nick Micheletti, John D. Heiss, William D. Figg, Elaine S. Jaffe, S. Percy Ivy, Richard Little, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2024) 144 (Supplement 1): 3122.
https://doi.org/10.1182/blood-2024-199168
Published: 2024
Journal Articles

A Pilot Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (VIPOR) for Diffuse Large B-Cell Lymphoma Involving the Central Nervous System

Disha Dalela, Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, James D. Phelan, Jagan R. Muppidi, Sarah Evans, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Seth M. Steinberg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2024) 144 (Supplement 1): 1724.
https://doi.org/10.1182/blood-2024-194482
Published: 2024
Journal Articles

Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jagan R. Muppidi, Max J Gordon, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Da Wei Huang, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Anna M Juanitez, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Allison P. Jacob, Heidi Simmons, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2024) 144 (Supplement 1): 1722.
https://doi.org/10.1182/blood-2024-197987
Published: 2024
Journal Articles

Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Allison Graeter, Christopher Melani, Max J Gordon, Jagan R. Muppidi, Sam Y. Ng, Sumaya Berg, Sarah Evans, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Bonita Bryant, Yandan Yang, Theresa Davies-Hill, Liza Lindenberg, Mark Ahlman, Esther Mena, Ethan Bergvall, Nick Micheletti, Laura M Yee, Allison P. Jacob, Monica Gallucci, Heidi Simmons, Alexander Bagaev, Mark Meerson, Ekaterina Postovalova, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2024) 144 (Supplement 1): 2958.
https://doi.org/10.1182/blood-2024-201711
Published: 2024
Journal Articles

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jagan R. Muppidi, Max J Gordon, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Da Wei Huang, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Anna M Juanitez, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Colleen Ramsower, Lisa M. Rimsza, Allison P. Jacob, Heidi Simmons, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2024) 144 (Supplement 1): 750.
https://doi.org/10.1182/blood-2024-197956
Published: 2024
Journal Articles

Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, George Wright, Jillian Simard, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Svetlana Pack, Cody J Peer, Oluwatobi Arisa, Esther Mena, Maria L. Lindenberg, Ethan Bergvall, Craig A. Portell, Rafic J Farah, Seung Tae Lee, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Anna M Juanitez, Crystal Lu, Allison P. Jacob, Heidi Simmons, William D Figg, Seth M. Steinberg, Elaine S Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Journal: Blood
Blood (2023) 142 (Supplement 1): 434.
https://doi.org/10.1182/blood-2023-180173
Published: 2023
Journal Articles

Preliminary Analysis of an Ongoing Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma

Rahul Lakhotia, Christopher Melani, Jagan R. Muppidi, Stefania Pittaluga, James D Phelan, Colleen Ramsower, Lisa M. Rimsza, Ryan S Robertorye, George Wright, Mark Meerson, Ekaterina Postovalova, Alexander Bagaev, Nathan Fowler, Liza Lindenberg, Esther Mena, Ethan Bergvall, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Sumaya Berg, Seth M. Steinberg, William Figg, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 1676.
https://doi.org/10.1182/blood-2023-185038
Published: 2023
Journal Articles

Nivolumab in Lymphomatoid Granulomatosis (LYG) and Other Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPDs) and Non-Hodgkin Lymphomas (NHLs) with Systemic and/or CNS Involvement: Preliminary Analysis of Efficacy and Safety from an Ongoing Phase II Study

Disha Dalela, Rahul Lakhotia, Stefania Pittaluga, Jagan R. Muppidi, James D Phelan, Amynah Pradhan, Sarah Evans, Candis Morrison, Atekelt Tadese, Seth M. Steinberg, Jeffrey Cohen, Elaine S. Jaffe, Wyndham H Wilson, Mark Roschewski, Christopher Melani
Journal: Blood
Blood (2023) 142 (Supplement 1): 4408.
https://doi.org/10.1182/blood-2023-180217
Published: 2023
Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Elizabeth Hill, Joseph L. Roswarski, Amrit Bhaskarla, Alexander Dew, Candis Morrison, Michael Emanuel, Ani Petrosyan, Hao-Wei Wang, Constance M. Yuan, Liza Lindenberg, Esther Mena, Baris Turkbey, Nisha Patel, Irina Maric, Alina Dulau-Florea, Katherine Calvo, Raul C. Braylan, Maryalice Stetler-Stevenson, Seth M. Steinberg, William Figg, Ryan M. Young, Ola Landgren, Mark Roschewski, Dickran Kazandjian
Journal: Blood
Blood (2023) 142 (Supplement 1): 337.
https://doi.org/10.1182/blood-2023-181811
Published: 2023
Journal Articles

Phase I Study of Response-Adapted Treatment with Venetoclax, Obinutuzumab, and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-Cell Malignancies

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, James D Phelan, Amynah Pradhan, Atekelt Tadese, Candis Morrison, Sarah Evans, Seth M. Steinberg, William Figg, Elaine S Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 6172.
https://doi.org/10.1182/blood-2023-178766
Published: 2023
Journal Articles

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

Emily Bryer, DO, Alexander Dew, DO, MS, Elizabeth Hill, MD, Elizabeth Gil Ramirez, MD, Candis Morrison, CNP, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Kevin Camphausen, MD, Jennifer Jones, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–11.
https://doi.org/10.1182/blood-2020-136176
Published: 2020
Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136182
Published: 2020
Journal Articles

Evaluation of Whole-Body MRI (WB-MRI) in Smoldering Multiple Myeloma (SMM)

Elizabeth Hill, MD, Baris Turkbey, MD, Evrim Turkbey, MD, Candis Morrison, CNP, PhD, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Dickran Kazandjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-136185
Published: 2020
Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Dickran Kazandjian, MD, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Neha Korde, MD, Sham Mailankody, MBBS, Elisabet E. Manasanch, MD, Mary L. Kwok, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Yong Zhang, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Crystal Lu, PharmD, BCOP, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Peter Choyke, MD, Alina Dulau-Florea, MD, Esther Mena, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Nisha Patel, DO, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, Seth M. Steinberg, PhD, William D. Figg, PhD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-136148
Published: 2020
Journal Articles

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

Elizabeth Hill, MD, Neha Korde, MD, Sham Mailankody, MBBS, Candis Morrison, CNP, PhD, Alexander Dew, DO, Jennifer Hsu Albert, RN, Katherine Graap, RN, Francesco Maura, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1794.
https://doi.org/10.1182/blood-2019-126952
Published: 2019
Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Dickran Kazandjian, MD, Neha Korde, MD, Sham Mailankody, MBBS, Yong Zhang, PhD, Jennifer Hsu, RN, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Sneha Divakarla, MHA, Mary L. Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Pallavi Galera, Alina Dulau-Florea, MD, Dalia Salem, MD, Esther Gonzalez, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Katherine R. Calvo, MD PhD, Raul C. Braylan, MD, Constance Yuan, MD PhD, Wyndham H. Wilson, MD PhD, Peter Choyke, MD, Maryalice Stetler-Stevenson, MD PhD, Seth M. Steinberg, PhD, William Figg, PharmD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1957.
https://doi.org/10.1182/blood-2018-99-111712
Published: 2018
Journal Articles

Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3339.
https://doi.org/10.1182/blood.V128.22.3339.3339
Published: 2016
Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4527.
https://doi.org/10.1182/blood.V128.22.4527.4527
Published: 2016
Journal Articles

Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities

Neha Korde, MD, Sham Mailankody, MD, Mark Roschewski, MD, Malek Faham, Chitra Kotwaliwale, Martin Moorhead, PhD, Mary L Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Rene Costello, Yong Zhang, MD PhD, Adriana Zingone, MD PhD, Debbie Burton, Marcia Mulquin, RN, Ashley Carpenter, RN, Diamond Zuchlinski, RN, Elizabeth Lamping, George Carter, PA, Candis Morrison, Karen Kurdziel, MD, Maria Lindenberg, MD, Roger Kurlander, MD, Irina Maric, MD, Katherine R. Calvo, MD, PhD, Raul C Braylan, MD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C Arthur, MD, Seth M. Steinberg, PhD, William D Figg, PharmD, Peter Choyke, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2105.
https://doi.org/10.1182/blood.V124.21.2105.2105
Published: 2014
Journal Articles

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies

Ian W. Flinn, John C. Byrd, Candis Morrison, Janet Jamison, Louis F. Diehl, Timothy Murphy, Steve Piantadosi, Eric Seifter, Richard F. Ambinder, Georgia Vogelsang, Michael R. Grever
Journal: Blood
Blood (2000) 96 (1): 71–75.
https://doi.org/10.1182/blood.V96.1.71
Published: 2000